Sector News

Merck KGaA appoints pharma head Oschmann as deputy CEO

September 18, 2014
Life sciences
(Reuters) – German drugs and chemicals maker Merck KGaA appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive, it said on Thursday.
 
Oschmann, 57, will share strategic management functions and representation of the company with CEO Karl-Ludwig Kley as of Jan. 1, 2015, it said.
 
The promotion puts Oschmann in the frame to possibly succeed Kley, whose contract runs until September 2016.
 
Belen Garijo, 54, will take over leadership of the entire pharma business, according to the statement. Garijo is already CEO of Merck’s biopharmaceutical division, Merck Serono, to which she will add consumer health, allergy treatments and biosimilars.
 
(Reporting by Georgina Prodhan; Editing by Ludwig Burger)

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach